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Background: Antioxidants may protect the aging brain

against oxidative damage associated with pathological
changes of Alzheimer disease (AD).

Main Outcome Measure: Diagnosis of AD by means
of multistage assessment procedures.
Results: Analyses of prevalent and incident AD yielded

Objective: To examine the relationship between anti-

oxidant supplement use and risk of AD.
Design: Cross-sectional and prospective study of dementia. Elderly (65 years or older) county residents were
assessed in 1995 to 1997 for prevalent dementia and AD,
and again in 1998 to 2000 for incident illness. Supplement use was ascertained at the first contact.
Setting: Cache County, Utah.
Participants: Among 4740 respondents (93%) with data

sufficient to determine cognitive status at the initial assessment, we identified 200 prevalent cases of AD. Among
3227 survivors at risk, we identified 104 incident AD cases
at follow-up.

T
Author affiliations are listed at
the end of this article.

similar results. Use of vitamin E and C (ascorbic acid)
supplements in combination was associated with reduced AD prevalence (adjusted odds ratio, 0.22; 95% confidence interval, 0.05-0.60) and incidence (adjusted hazard ratio, 0.36; 95% confidence interval, 0.09-0.99). A
trend toward lower AD risk was also evident in users of
vitamin E and multivitamins containing vitamin C, but
we saw no evidence of a protective effect with use of vitamin E or vitamin C supplements alone, with multivitamins alone, or with vitamin B–complex supplements.
Conclusions: Use of vitamin E and vitamin C supplements in combination is associated with reduced prevalence and incidence of AD. Antioxidant supplements merit
further study as agents for the primary prevention of AD.
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of Alzheimer disease (AD)
will grow as people live
longer. 1 Consequently,
strategies for the prevention of AD are important. Because judicious doses of antioxidant vitamin supplements are relatively nontoxic and may have
wide-ranging health benefits, antioxidants may offer an attractive prevention
strategy.
Antioxidants scavenge free radicals
and other reactive oxygen species that
damage cellular membranes, organelles,
and macromolecules. Accumulation of reactive oxygen species may overwhelm the
protective reserves of antioxidants in cells
(oxidative stress). In neurons, which are
especially vulnerable to free radical–
mediated damage, these processes may be
important in aging of the brain and the
pathogenesis of AD.2 Thus, intake of antioxidants in the diet or, more power-
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fully, in nutritional supplements may be
neuroprotective.3,4
Antioxidants may mitigate agerelated cognitive decline,5-12 and a randomized trial showed that selegiline
hydrochloride or vitamin E may slow
the progression of AD.13 However, few
epidemiologic studies have examined
whether antioxidants may delay AD
onset. Three prospective studies found
lower risks of dementia or AD in participants consuming more dietary
antioxidants.14-16 Another study of 633
participants found no incident AD cases
during 4 years among individuals who
reported use of vitamin E or vitamin C
(ascorbic acid) supplements at baseline, 17 while an investigation of 3385
men found reduced prevalence of vascular and mixed dementias, but not AD,
among users of both vitamin E and C
supplements. 18 These results contrast
with a recent study showing no associa-
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tion between AD and antioxidant vitamin consumption in either dietary or supplement form.19
To extend these findings, we examined data from
the Cache County Study, a large, population-based investigation of the prevalence and incidence of AD and
other dementias in relation to genetic and environmental antecedents. Using both prevalence and incidence data,
we analyzed the association of antioxidant supplement
use and occurrence of AD.

METHODS
STUDY POPULATION
In 1995 the study enrolled 5092 elderly residents of Cache
County, Utah (90% those aged 65 years and older). We obtained buccal DNA for determination of genotype at the gene
for apolipoprotein E (APOE) from 97% of these respondents
and used a multistage screening and assessment protocol to identify and diagnose prevalent cases of dementia (wave I). Three
years later, between 1998 and 2000, we used similar procedures to identify and diagnose incident cases of dementia (wave
II). The institutional review board of each collaborating site approved the study, and all participants and/or their collateral informants provided informed consent.
The assessment procedures for both waves have been detailed elsewhere.20,21 Briefly, screening began with an interview that included the modified Mini-Mental State Examination (3MS)22,23 or, for those unable to participate, a questionnaire
administered to a collateral informant.24 Individuals who did
poorly on this screen (eg, scoring ⬍87 on the 3MS at wave I)
were examined further by telephone interview with a collateral informant by means of the Dementia Questionnaire (DQ).25
All those older than 90 years plus a weighted stratified subsample of 19% of all participants were also studied with the DQ,
regardless of their initial screening results. Participants with
DQ scores of 4 or more at wave I or 3 or more at wave II, as
well as all members of the 19% subsample, were then examined at their place of residence. The examination included a
medical history, a chronologic history of cognitive symptoms,
and a structured neurologic examination, all administered by
specially trained nurses, and a 1-hour battery of neuropsychological tests administered by psychometric technicians. A geriatric psychiatrist (J.C.S.B.) and neuropsychologist (J.T.T.) reviewed these data and assigned working diagnoses of dementia
(Diagnostic and Statistical Manual of Mental Disorders, Revised
Third Edition26) or other cognitive syndromes. Participants with
working diagnoses of prevalent or incident dementia were further examined by a geriatric psychiatrist (J.C.S.B.) and were
referred for laboratory studies including neuroimaging. These
and other participants with apparent cognitive compromise received an identical clinical assessment 18 months later to assess longitudinal course. A consensus panel of experts in neurology, geriatric psychiatry, neuropsychology, and cognitive
neuroscience then reviewed all available data and assigned final differential diagnoses. Diagnoses of AD used standard criteria,27 while diagnoses of other dementing illnesses were also
made according to current research practice.20,21
Data from the fully examined 19% subsample suggested
an overall sensitivity of 93% for the study’s screening and examination protocol for detection of prevalent dementia28 and
89% for the detection of incident dementia.29 A comparison of
dementia diagnoses with neuropathologic findings in 54 individuals suggested that the accuracy of prevalent and incident
AD diagnoses was comparable to typical rates reported from
university AD clinics (eg, positive predictive value of 90%; un-
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published data, Brenda L. Plassman, PhD, A.S.K., Janette J.
Townsend, MD, M. J. Ball, MD, David C. Steffens, MD, Carol
E. Leslie, MS, J.T.T, M.C.N., James R. Burke, MD, K.A.W., and
J.C.S.B., 2003).
PREVALENCE DATA
Among the initial 5092 wave I respondents, we identified 355 individuals with prevalent dementia. Of these, 200 received diagnoses of AD and no other dementing illness. Of the remaining
respondents, 4540 individuals completed study procedures sufficiently to demonstrate that they were free of dementia at the
completion of the wave I assessments. Of these, 719 were members of the fully examined 19% subsample, while 3821 others
showed no evidence of dementia on screening and assessment
measures and therefore received no further evaluation at wave I.
INCIDENCE DATA
At the end of wave II assessments, we identified 185 participants with incident dementia, of whom 104 received diagnoses of AD and no other dementing illness. Another 3123 wave
II participants completed study procedures sufficiently to show
that they remained free of dementia. Of these, 394 were members of the 19% subsample and were thus examined directly,
while 2729 others showed no evidence of dementia on screening measures.
During the course of the study, 1429 individuals were lost
to follow-up. Of these, 627 (43.9%) died, while the other 802
(56.1%) refused to complete the protocol, moved out of the area,
or could not be located. Individuals among the latter group were
older (t=−5.92, P⬍.001) and less educated (t=5.29, P⬍.001) and
had performed less well on their cognitive screen with the 3MS
(t=6.21, P⬍.001) than those who completed the protocol.
EXPOSURE ASSESSMENT
At the initial visit of wave I, we administered a standardized interview covering suspected risk factors for dementia. The interview included sections on sociodemographic factors including education, occupational history, medical history, tobacco and alcohol
use, and medication use. The section on medications asked participants about use during the preceding 2 weeks of any prescription or over-the-counter medications, including vitamin supplements. Interviewers then asked to see the containers of these
treatments, and recorded information about the use of each.
We categorized participants according to their use of vitamin supplements, counting individuals as vitamin E users if
they reported taking an individual supplement of vitamin E or
a multivitamin preparation that contained more than 400 IU
of vitamin E. Similarly, vitamin C users reported taking vitamin C supplements or multivitamin preparations containing
at least 500 mg of ascorbic acid. Individuals classified as multivitamin users reported similar use of a multivitamin preparation containing lower doses of vitamin E or C. Finally, we
classified individuals as users of vitamin B formulations if they
took a supplement preparation that specifically contained a complex of multi-B vitamins (riboflavin, pyridoxine, cyanocobalamin, etc). We examined B vitamins and multivitamins as “control” exposures to assess the specificity of any association
between use of higher doses of antioxidant supplements and
risk of AD, and to differentiate this association from a tendency toward supplement use in general.
STATISTICAL ANALYSES
We compared the sociodemographic characteristics of
supplement users vs nonusers with 2 tests for categorical
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Table 1. Characteristics of the 4740 Elderly Participants in the Prevalence Data According to Vitamin Supplement Use
at the Baseline (Wave I) Visit

No. (%)
Women, No. (%)
Mean (SD) age, y
Mean (SD) years of education, y
Fair or poor health, No. (%)
Current smoker, No. (%)
No. of ⑀4 alleles, No. (%)
0
1
2
Missing

Vitamin E or C*

Multivitamins

No Supplements†

Missing Data

824 (17.4)
500 (60.7)‡
74.2 (6.5)‡
13.5 (2.9)‡
153 (18.6)‡
17 (2.1)

967 (20.4)
619 (64.0)‡
75.9 (6.9)
13.3 (2.8)
271 (28.0)‡
19 (2.0)

2828 (59.7)
1517 (53.6)
75.4 (7.2)
13.1 (2.9)
698 (24.7)
74 (2.6)

121 (2.6)
76 (62.8)
76.6 (7.4)
13.3 (2.8)
39 (32.2)
2 (1.7)

535 (64.9)
259 (31.4)
21 (2.5)
9 (1.1)

654 (67.6)
263 (27.2)
31 (3.2)
19 (2.0)

1894 (67.0)
803 (28.4)
73 (2.6)
58 (2.1)

77 (63.6)
36 (29.8)
2 (1.7)
6 (5.0)

*The characteristics of vitamin E and vitamin C (ascorbic acid) users were very similar; we therefore combined them into one group for this comparison.
†No use of multivitamins, vitamin E, or vitamin C.
‡Difference compared with nonusers of a vitamin supplement significant at P⬍.05.

variables and 2-sample t tests for continuous variables. We
then compared the odds of prevalent AD among current
users vs nonusers of the various vitamin supplements by
means of multiple logistic regression, building on a “base”
model for AD prevalence that had previously been developed. 20 This model included terms for age, the squared
deviation of age from the population mean, sex, education,
dummy-coded terms for the presence of 1 and 2 APOE ⑀4
alleles, and interactions between age and the dummy-coded
APOE ⑀4 terms. We also added an indicator term for “fair” or
“poor” health (self-rated at interview) that proved to be
inversely associated with antioxidant supplement use
(Table 1). We analyzed the incidence data by means of
discrete-time survival analysis30 to compare annual risks of
developing AD during the wave I–wave II interval related to
supplement use reported at baseline. The discrete-time
approach considered each person-year of observation, with
participants entering the analytic pool at the age of their initial wave I interview. Observations were considered year by
year thereafter until participants either developed AD or
underwent wave II screening without evidence of dementia.
Adjusted hazard ratios with various exposures were estimated by means of discrete-time multiple logistic regression
models, again relying on a base model developed previously21 and containing covariates identical to the prevalence
model. All logistic models were fitted using SAS version 8.0
or 8.1 software (SAS Institute Inc, Cary, NC). Parameter
estimates are reported with 95% profile likelihood confidence intervals.
RESULTS

More than 97% of participants provided sufficient exposure data to classify their supplement use (Table 1). The
remainder tended to be female, older, and in poorer health.
Of those who provided data, approximately 17% reported taking vitamin E or C supplements. Compared with
nonusers, these individuals were significantly more likely
to be female, younger, and better educated, and to report better general health. Another 20% of the participants reported use of multivitamins without high-dose
vitamin E or C. These multivitamin users were also more
likely to be female, but reported poorer general health.
There were few current smokers overall and little difference in rates of smoking between supplement users and
nonusers.
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PREVALENCE ANALYSES
In unadjusted analyses, use of vitamin E, vitamin C, and
multivitamins were all inversely associated with prevalent AD (Table 2). However, after adjustment for age,
sex, years of education, number of APOE ⑀4 alleles,
APOE ⫻ age interaction terms, and general health status, the inverse association remained significant only for
use of vitamin E and multivitamins. There was no association between use of B-complex vitamins and AD prevalence, either before or after adjusting for the covariates
in the base model.
Of the participants who reported current use of vitamin E, vitamin C, or multivitamin supplements, more
than a third took 2 or more of these in combination. We
therefore examined the relationship between AD prevalence and the use of these supplements alone and in combination. After adjusting for the covariates in the base
model, there was no appreciable association with the use
of vitamin C alone, vitamin E alone, or vitamin C and
multivitamins in combination. There was, however, a significant, if relatively modest, inverse association with the
use of multivitamins alone, and a suggestion of a stronger inverse association with the combination of vitamin
E and multivitamins (the broad confidence interval presumably reflecting relatively small numbers). By far, the
strongest inverse association with AD prevalence was observed with use of both vitamin E and vitamin C, with
or without concomitant use of multivitamins (multivariable adjusted odds ratio, 0.22; 95% confidence interval,
0.05-0.60).
INCIDENCE ANALYSES
Any baseline (wave I) use of vitamin E was associated
with a reduced AD incidence that fell just short of statistical significance (Table 3), either before or after adjustment for the covariates in the base model. However,
the adjusted point estimate for risk was similar to the estimate obtained with prevalence data (adjusted hazard
ratio, 0.53 vs 0.44). The incidence of AD was not associated with use of vitamin C, B-complex, or (in contrast
to the prevalence analyses) multivitamins. When we exWWW.ARCHNEUROL.COM
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Table 2. Association Between Vitamin Supplement Use and Prevalent Alzheimer Disease
No. With AD/Total No.*
Any vitamin E
No
Yes
Any vitamin C (ascorbic acid)
No
Yes
Any multivitamins
No
Yes
Any B-complex vitamins
No
Yes
Supplements in combination
No vitamin E, C, or multivitamins
Multivitamins, no vitamin E or C
Vitamin C, no vitamin E or multivitamins
Vitamin E, no vitamin C or multivitamins
Vitamin C and multivitamins, no vitamin E
Vitamin E and multivitamins, no vitamin C
Vitamins E and C‡

Unadjusted OR (95% CI)

Adjusted OR† (95% CI)

186/4127
8/492

1.0
0.35 (0.15-0.67)

1.0
0.44 (0.19-0.86)

175/3951
19/668

1.0
0.63 (0.38-0.99)

1.0
0.80 (0.46-1.30)

152/3219
42/1400

1.0
0.62 (0.44-0.88)

1.0
0.63 (0.43-0.90)

188/4430
6/189

1.0
0.74 (0.29-1.55)

1.0
1.05 (0.39-2.35)

138/2828
32/967
9/146
4/73
7/186
1/83
3/336

1.0
0.67 (0.44-0.97)
1.28 (0.60-2.43)
1.13 (0.34-2.78)
0.76 (0.32-1.54)
0.24 (0.01-1.08)
0.18 (0.04-0.47)

1.0
0.60 (0.39-0.91)
1.47 (0.63-3.08)
1.15 (0.32-3.21)
0.99 (0.39-2.15)
0.34 (0.02-1.64)
0.22 (0.05-0.60)

Abbreviations: AD, Alzheimer disease; CI, confidence interval; OR, odds ratio (estimated from logistic regression models).
*Total does not include 121 participants in the prevalence sample who did not provide data on supplement use.
†Adjusted for age, the squared deviation of age from the population median, sex, education, dummy-coded terms for the presence of 1 and 2 apolipoprotein E
⑀4 alleles, interactions between age and the dummy-coded apolipoprotein E ⑀4 terms, and an indicator term for general health status.
‡Includes 164 individuals who also reported multivitamin use.

Table 3. Association Between Vitamin Supplement Use and Incident Alzheimer Disease
No. With AD/Total Person-Years*
Any vitamin E
No
Yes
Any vitamin C (ascorbic acid)
No
Yes
Any multivitamins
No
Yes
Any B-complex vitamins
No
Yes
Supplements in combination
No vitamin E or C or multivitamins
Multivitamins, no vitamin E or C
Vitamin C, no vitamin E or multivitamins
Vitamin E, no vitamin C or multivitamins
Vitamin C and multivitamins, no vitamin E
Vitamin E and multivitamins, no vitamin C
Vitamins E and C‡

Unadjusted HR (95% CI)

Adjusted HR† (95% CI)

93/8778
6/1172

1.0
0.48 (0.19-1.02)

1.0
0.53 (0.20-1.12)

88/8411
11/1539

1.0
0.68 (0.34-1.23)

1.0
0.74 (0.37-1.35)

70/6818
29/3132

1.0
0.90 (0.58-1.38)

1.0
0.79 (0.50-1.22)

95/9490
4/460

1.0
0.87 (027-2.09)

1.0
0.94 (0.28-2.29)

64/5928
21/2127
3/312
2/159
5/411
1/197
3/816

1.0
0.91 (0.55-1.47)
0.89 (0.22-2.42)
1.17 (0.19-3.77)
1.13 (0.39-2.55)
0.47 (0.03-2.14)
0.34 (0.08-0.92)

1.0
0.77 (0.45-1.27)
1.25 (0.30-3.52)
1.20 (0.19-4.13)
0.94 (0.32-2.20)
0.47 (0.03-2.22)
0.36 (0.09-0.99)

Abbreviations: AD, Alzheimer disease; CI, confidence interval; HR, hazard ratio (estimated from discrete-time survival analysis).
*Total person-years does not include contributions from 75 participants in the incidence sample who did not provide supplement use data.
†Adjusted for age, the squared deviation of age from the population median, sex, education, dummy-coded terms for the presence of 1 and 2 apolipoprotein E
⑀4 alleles, interactions between age and the dummy-coded apolipoprotein E ⑀4 terms, and an indicator term for general health status.
‡Includes 125 individuals (397 person-years) who also reported multivitamin use.

amined the risks with respect to vitamin E, vitamin C,
and multivitamin use alone or in combination, the results were again similar to those from the prevalence analyses. There was a trend toward reduced AD incidence with
vitamin E and multivitamins in combination, and a greater
apparent reduction with use of vitamin E and vitamin C
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together (adjusted hazard ratio, 0.36; 95% confidence interval, 0.09-0.99). Use of multivitamins alone was not notably related to AD risk. We found no difference in degree of association between supplement use and AD risk
across different strata of age, sex, or APOE genotype (data
not shown).
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COMMENT

These analyses from the Cache County Study examined
the degree to which use of vitamin supplements, especially vitamins E and C, was associated with occurrence
of AD. Both prevalence and incidence analyses suggested that use of vitamin E supplements is associated
with reduced occurrence of AD. This inverse association with vitamin E appears attributable almost entirely
to the use of vitamin E and C supplements in combination (the latter in single-agent supplements or in
multivitamins). There was no notable reduction in risk
of incident AD with vitamin E or vitamin C alone or with
multivitamins. There was also no association between AD
risk and use of B-complex vitamins.
The current Institute of Medicine recommended daily
allowance for vitamin E is 22 IU (15 mg), and for vitamin
C (ascorbic acid), 75 to 90 mg.31 Multivitamin preparations typically contain these approximate quantities of both
vitamins E and C (more vitamin C in some instances), while
individual supplements typically contain doses up to 1000
IU of vitamin E and 500 to 1000 mg or more of vitamin C
(ascorbic acid). Our findings suggest that vitamins E and
C may offer protection against AD when taken together
in the higher doses available from individual supplements. There may also be some protective effect with vitamin E combined with the lower doses of vitamin C typically in multivitamins, although small numbers of such
users in this sample (n=197) limit the inference. Vitamin
E, a lipid-soluble molecule, is one of the strongest nutritional antioxidants. Sufficient levels of vitamin E may reduce the oxidative stress–related damage associated with
pathological changes of AD.2 Because vitamin C is water
soluble and rapidly excreted after ingestion,32 its effect may
be limited to the reduction of lipid-soluble vitamin E after the latter has been oxidized.33 There is, therefore, some
biological rationale for benefit from combining vitamin E
and C dosage, as observed herein.
Two previous observational studies have examined the relationship between dementia and use of vitamin E and C supplements. The East Boston Study17 found
no incident AD among participants who reported use of
vitamin E or vitamin C at baseline, but the adjusted risk
reduction was statistically significant only for vitamin C
use. However, more than half of those who used vitamin C also reported taking vitamin E. The East Boston
results are therefore not inconsistent with our current
findings. Our findings are also reminiscent of those from
the Honolulu-Asia Aging Study, although that study observed a relationship of combined vitamin E and C use
with vascular dementia but not AD.18
Four previous prospective studies14-16,19 have considered the relationship between dementia and dietary
antioxidant intake. Dietary sources typically provide much
lower levels of antioxidants than individual supplements. Nonetheless, 3 of these studies found evidence
suggesting reduced risk of dementia or AD with high dietary intake of antioxidants. One report noted inverse association of dementia with dietary intake of flavonoids
(mostly from red wine).14 Because few of our participants drank wine or took supplements with flavonoids,
we could not assess this association.
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A prospective study from the Chicago Health and
Aging Project (CHAP) found reduced risk of AD associated with dietary intake of vitamin E, but not vitamin C.16
Curiously, when vitamin E intake from supplement
sources was considered in that study, the inverse association with AD disappeared. The authors noted a dramatic increase in vitamin E supplement use during the
study’s course. It is therefore possible that these supplements had not been used long enough to afford protection, or perhaps they were initiated in response to cognitive difficulties (reflecting recent reports of a beneficial
effect13). By contrast, more than 97% of vitamin E and C
users in Cache County reported use of these supplements for 2 or more years (such long-term use of antioxidants by Cache County participants precluded any
meaningful analyses of the relationship between duration of supplement use and AD risk). The CHAP found
no statistical interaction between vitamin E and C intake, modeled as continuous variables. Because our data
suggest effect modification only with supplement levels
of vitamin E and C, an interaction between the 2 might
not be apparent with continuous intake estimates including lower dietary amounts. Finally, the CHAP suggested an inverse association with vitamin E only among
participants lacking an APOE ⑀4 allele. We have no explanation for our inability to reproduce this finding.
The Rotterdam Study15 found dietary intake of vitamin E and, to a lesser extent, vitamin C to be inversely
associated with AD, after controlling for antioxidant
supplement use. Like the CHAP, this study saw no interaction between vitamin E and vitamin C use. It is unclear, however, whether such interaction was tested by
means of continuous variable modeling, as discussed earlier. The greatest AD risk reductions in the Rotterdam
Study appeared among individuals in the highest tertiles of vitamin E and C intake, and it is therefore possible that these groups were similar to our categories of
vitamin E and C supplement users. Because there were
few smokers in Cache County, we were unable to test
the Rotterdam finding of accentuated inverse association of AD and antioxidant vitamin intake among current smokers.
The newest prospective study of antioxidant vitamins, from the Washington Heights–Inwood Columbia
Aging Project,19 did not find a significant reduction in
AD risk with use of vitamin E or C from either supplemental or dietary sources, although the relative risk estimates associated with the highest levels of these vitamins were not inconsistent with previous reports. The
authors of the Washington Heights–Inwood Columbia
Aging Project report did not test for interaction between intake of vitamins E and C, although they did examine the cumulative effects of various vitamin supplements alone and in combination, reporting no reduction
in AD risk with combined use. Unfortunately, no details
of these analyses (undertaken post hoc) were provided,
so it is difficult to find explanations for the difference between their findings and ours.
Our study has several strengths (eg, populationbased, large sample, prospective design), but there are
also potential limitations. The prevalence data were crosssectional, and the incidence data covered only a relaWWW.ARCHNEUROL.COM
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tively short (3-year) period of follow-up. Consequently,
our findings could represent spuriously reduced report
of antioxidant vitamin use by participants with AD at the
prevalence wave, or by those with prodromal cognitive
difficulties that later “converted” to incident AD. To explore this potential problem, we reanalyzed the incidence data while controlling for baseline 3MS score, but
we found no notable changes in the associations between supplement use and AD incidence. We therefore
doubt that incipient cognitive difficulties at baseline provide a likely explanation for our findings.
Invariably, observational studies cannot exclude the
possibility that inverse associations observed with AD simply reflect some circumstance, characteristic, or condition associated with vitamin use in general. For example,
Cache County antioxidant supplement users were younger,
more educated, and in better general health (all potentially associated with reduced AD risk) than nonusers. However, statistical control on these characteristics failed to
attenuate the association between use of vitamin E and C
in combination and AD risk reduction. Such control may
still fail, however, to consider other, unmeasured confounders such as a tendency toward a healthy lifestyle
among supplement users. We doubt that such unsuspected confounding fully explains our findings because
(1) our relatively objective method of exposure classification should afford some protection against selective underreporting of use; (2) we saw little evidence of such confounding when we considered nutritional supplements
such as multivitamins, calcium supplements,34 and Bvitamin formulations; and (3) our relatively consistent (and
biologically plausible) finding of strongest association with
vitamins E and C combined appears to argue against a
simple artifact as the source of our results.
In summary, our findings using both prevalence and
incidence data from the large, population-based Cache
County study suggest that antioxidant vitamins, specifically the combination of vitamin E and C supplements,
may prevent AD. As is widely appreciated, formal proof
of such an effect can come only from randomized prevention trials. If proven efficacious in such trials, antioxidant vitamins (believed to offer other health benefits35) would offer an attractive prevention strategy for
AD. Formal demonstration of their efficacy would therefore have significant public health implications, and we
suggest that prevention trials are warranted.
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